[Clinical application of KM 2210 (estradiol-chlorambucil) in patients with advanced prostatic carcinoma].

Abstract

KM 2210, a combination product of 17 beta-estradiol and chlorambucil, was administered to 15 patients with advanced (stage C and D) prostatic carcinoma. We studied the clinical efficacy and the drug concentration in the blood and prostatic tissues. The administered doses were 100 mg or 150 mg p.o., in 2 or 3 divided doses/day (or every other day in a few cases) for periods ranging from 30 to 369 days; the maximum total dose was 42.5 g. Objective clinical responses, according to the criteria by Shida et al., were observed in 6 (40%) patients. Side effects included gastrointestinal symptoms, e.g. loss of appetite or nausea, anemia and leukopenia. No obvious hepatic disorder was observed.

• Authors: K Isurugi
• Journal: Gan no rinsho. Japan journal of cancer clinics (Gan No Rinsho) Vol. 30 Issue 7 Pg. 810-8 (Jun 1984) ISSN: 0021-4949 [Print] Japan
• PMID: 6547748 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Chlorambucil
• Estradiol
• bestrabucil

Topics

• Aged
• Animals
• Child
• Chlorambucil (analogs & derivatives, blood, metabolism, therapeutic use)
• Estradiol (analogs & derivatives, blood, metabolism, therapeutic use)
• Humans
• Male
• Middle Aged
• Prostate (metabolism)
• Prostatic Neoplasms (drug therapy, metabolism, secondary)
• Rats